Summary

Primary aldosteronism is a common cause of hypertension. Recent evidence suggests that many patients with bilateral idiopathic hyperaldosteronism harbor gain-of-function somatic mutations in zona glomerulosa calcium channels that results in aldosterone production. This finding raises the possibility that calcium channel antagonists may be a targeted therapy to reduce aldosterone production in patients who harbor these mutations.

Study Name: Calcium Channel Blockade in Primary Aldosteronism (CCB-PA)
Status: Recruiting
Conditions: Primary aldosteronism
Interventions: Drug: Amlodipine
Locations: Brigham and Women’s Hospital, University of Michigan
Study link: https://clinicaltrials.gov/ct2/show/NCT04179019

To search for other studies by topic, location, or status, go to our Clinical Studies page.

©2021 Primary Aldosteronism Foundation — All Rights Reserved

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.

©2021 Primary Aldosteronism Foundation

The Primary Aldosteronism Foundation is a registered 501(c)(3) public charity. Donations are tax deductible in the US.